Compare Otis Worldwide Corp (OTIS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Sana Biotechnology Inc — how do they compare? Otis Worldwide Corp trades at $70.74 (market cap $27.61B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Otis Worldwide Corp is far larger — about 31.4× Sana Biotechnology Inc's market cap, and Otis Worldwide Corp pays a 2.36% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| OTIS | SANA | |
|---|---|---|
Market Cap | $27.61B | $879.40M |
Sector | Industrials | Health |
52-Week High | $100.99 | $5.92 |
52-Week Low | $69.34 | $2.68 |
Enterprise Value | $34.99B | $853.59M |
Dividend Yield | 2.36% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
